1. Home
  2. SLDB vs MNPR Comparison

SLDB vs MNPR Comparison

Compare SLDB & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

HOLD

Current Price

$5.70

Market Cap

464.1M

Sector

Health Care

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$75.21

Market Cap

531.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDB
MNPR
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
464.1M
531.6M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
SLDB
MNPR
Price
$5.70
$75.21
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
11
13
Target Price
$14.82
$97.83
AVG Volume (30 Days)
987.6K
163.8K
Earning Date
11-03-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.41
$21.00
52 Week High
$7.37
$105.00

Technical Indicators

Market Signals
Indicator
SLDB
MNPR
Relative Strength Index (RSI) 59.24 43.53
Support Level $5.47 $73.63
Resistance Level $6.04 $79.31
Average True Range (ATR) 0.34 5.90
MACD 0.08 -0.83
Stochastic Oscillator 68.99 9.91

Price Performance

Historical Comparison
SLDB
MNPR

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: